Attana receives a Cell™ 250 instrument order from a European Life Science company

Attana has received an order for a Cell™ 250 instrument from a European Life Science company. This is the client’s second Attana instrument and is the result of a successful use and the client’s growth plans.

The Cell™ 250 instrument will be installed during Q1 2022 and will positively affect Attana earnings in Q1 2022 and cash flow for the remainder of the year.

“We strive to be close partner with our clients. This order is a result of this and our ability to grow together with our clients. We see good potential in increased further collaboration” comments Teodor Aastrup, CEO Attana.

For more information, please contact:

Teodor Aastrup, CEO Attana AB
e-mail: teodor.aastrup@attana.com 
tel: + 46 8 674 57 00

This is information that Attana AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at the time stated by the Company’s news distributor, Cision, at the publication of this press release.

About Attana

Attana was founded in 2002 with the vision of in vitro characterization of molecular interactions mimicking in vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays and the Attana Virus Analytics (AVA) platform, a proprietary in vitro diagnostics (IVD) tool. Attana products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about our latest services and products, please visit www.attana.com or contact sales@attana.com

Tags: